Abstract
Objectives Evaluation of changes in symptoms among patients with overactive bladder syndrome treated with transdermal oxybutynin and tolerability after 12 months of follow-up. Methods This was a multicenter, retrospective, single-cohort, observational study. Changes in symptoms were evaluated primarily with a 3-day voiding diary. Results were compared to baseline. Subgroup analyses were performed in patients previously treated for OAB or not and aged < 65 years versus ≥65 years. Results Clinical records of 105 patients were examined; 92.4% were women. At 12 months, 58 patients continued to receive transdermal oxybutynin. Changes in symptoms according to the voiding diary were evaluated in 47 patients. Significant improvements from baseline were observed in urinary frequency (−2.6 voids/24 hours (95% CI: −3.5; −1.8), p < 0.001); daily number of urgent episodes (−4.7 episodes/day (95% CI: −6.1; −3.6), p < 0.001); and urge incontinence (−1.9 episodes/day (95% CI: −2.9; −1.3), p < 0.001). No statistically significant differences were found in subgroup analyses. In total, 38.1% of patients had adverse events, primarily in the application site (27.6%). No severe systemic adverse events occurred. Only 6 patients (5.7%) reported dry mouth. Conclusions Improved symptoms and good tolerability observed after 1 year of treatment with transdermal oxybutynin shows that it currently has a place in the treatment of OAB patients.
Highlights
Overactive bladder syndrome (OAB) has been clinically defined as urinary urgency, with or without incontinence, generally accompanied by an increase in urinary frequency and nocturia, after any local disease or metabolic disorder that would explain these symptoms has been ruled out [1]
Randomized clinical trials are still the gold standard, generalization of results from these studies may be limited by widely varying mid- and long-term responses in real-world situations, lack of treatment adherence, or the use Advances in Urology of drugs in patients with diverse morbidities. erefore, the aim of this study was to ascertain if the improvement in symptoms and good tolerability shown in clinical trials are reproduced under clinical practice conditions
We examined retrospective data from the realworld management of patients with OAB treated with OXYTDS over a 12-month period
Summary
Overactive bladder syndrome (OAB) has been clinically defined as urinary urgency, with or without incontinence, generally accompanied by an increase in urinary frequency and nocturia, after any local disease or metabolic disorder that would explain these symptoms has been ruled out [1]. Transdermal delivery has been shown to significantly reduce side effects by decreasing the active metabolite of oxybutynin (N-DEO) involved in their onset, possibly improving treatment adherence [6]. Randomized clinical trials are still the gold standard, generalization of results from these studies may be limited by widely varying mid- and long-term responses in real-world situations, lack of treatment adherence, or the use Advances in Urology of drugs in patients with diverse morbidities. Transdermal delivery has been shown to significantly reduce side effects by decreasing the active metabolite of oxybutynin (N-DEO) involved in their onset, possibly improving treatment adherence [6]. e efficacy and safety of OXYTDS in the treatment of OAB have been established in several clinical trials [7,8,9].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
